ArticleNeurology. Clinical practice2017
Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.
Article in Neurology. Clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Tumefactive Multiple Sclerosis Mimicking an Intracranial Mass in a 34-Year-Old Man: A Case Report.Cureus · 2026Article
- Challenges in the Diagnosis of Multiple Sclerosis: A Case Report.Acta medica Lituanica · 2026Article
- Tumefactive Demyelinating Lesion Mimicking Low-Grade Astrocytoma with a T2/FLAIR Mismatch Sign: A Case Report and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Deep Learning MRI Models for the Differential Diagnosis of Tumefactive Demyelination versusAJNR. American journal of neuroradiology · 2025Article
- Flow cytometry identifies changes in peripheral and intrathecal lymphocyte patterns in CNS autoimmune disorders and primary CNS malignancies.Journal of neuroinflammation · 2024Article
- Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.Journal of neurology · 2024Article
- Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.Neurology · 2023Article
- Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine.Current oncology (Toronto, Ont.) · 2023Review
- Case report: Diagnostic challenge: a new multiple sclerosis "relapse" leading to the diagnosis of anaplastic astrocytoma.Frontiers in neurology · 2023Article
- Diagnostic Challenges and Radiological Spectrum of Tumefactive Multiple Sclerosis: A Case Report Study.Cureus · 2022Article
- 'Killer' open ring in the brain.BMJ case reports · 2022Article
- Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.Surgical neurology international · 2022Article
- Differential imaging of atypical demyelinating lesions of the central nervous system.La Radiologia medica · 2021Review
- Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.Surgical neurology international · 2021Article
- Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.EJNMMI radiopharmacy and chemistry · 2019Review
- Tumefactive demyelination in older adults: A scoping review of published cases.Multiple sclerosis journal - experimental, translational and clinicalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are limited data to guide clinicians in differentiating tumefactive multiple sclerosis (TMS) from CNS neoplasms. Identifying distinguishing features will inform diagnosis and management and avoid unnecessary diagnostic biopsy. Our study aimed to determine the clinical and radiologic features that differentiate TMS from glioma and CNS lymphoma (CNSL) in patients who present with tumefactive lesions.
methodsWe retrospectively reviewed all patients with tumefactive lesions and histologically proven or clinically diagnosed TMS, glioma, or CNSL at our tertiary center from 1999 to 2012. Two independent blinded neuroradiologists rated MRI brain scans at presentation. We correlated patients' demographic, clinical, laboratory, and radiologic data to final diagnosis.
resultsA total of 133 patients (10 TMS, 85 glioma, 38 CNSL) were analyzed. Patients with TMS were younger and a greater proportion were women. Presenting symptoms did not distinguish between diagnoses. TMS lesions were smaller compared to glioma and CNSL, had no or mild mass effect, and were always associated with contrast enhancement. Radiologic features that were more frequent in TMS lesions were incomplete rim (open-ring) enhancement, incomplete peripheral diffusion restriction, and mixed T2 signal and CT hypoattenuation of MRI-enhancing components (all
conclusionsRadiologic features but not presenting symptoms are useful in distinguishing TMS from CNS neoplasms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.